Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 5 de 5
Filter
Add more filters










Database
Language
Publication year range
1.
Pharm Res ; 35(11): 226, 2018 Oct 02.
Article in English | MEDLINE | ID: mdl-30280277

ABSTRACT

PURPOSE: Filgrastim, a recombinant human granulocyte-colony stimulating factor, is widely used to treat congenital and acquired neutropenia. Following patent expiration of the innovator filgrastim product, biosimilar filgrastim products have been approved in the EU and shown to be comparable with the innovator with respect to quality, safety and efficacy. In less regulated markets, copy filgrastim products are available but data about their quality are scarce. In the present study, we provide a head-to-head comparative study on the quality of biosimilar and copy filgrastim products. METHODS: Innovator filgrastim product, Neupogen®, two EU-licensed biosimilars, Zarzio® and Tevagrastim®, and two copy filgrastim products, Biocilin® and PDgrastim®, were subjected to peptide mapping, circular dichroism spectroscopy, fluorescence spectroscopy, sodium dodecyl sulfate polyacrylamide gel electrophoresis, high performance size-exclusion chromatography, reversed-phase ultra-performance liquid chromatography, endotoxin test, flow imaging microscopy and in vitro potency assay. RESULTS: Zarzio® and Tevagrastim® have comparable quality to Neupogen®, while Biocilin® showed a significantly lower and PDgrastim® a higher specific activity. Moreover, PDgrastim® showed a higher level of impurities and a lower thermo stability than the other products. CONCLUSIONS: Except for the deviating specific activities of the two copy filgrastim products, we found no substantial differences in product quality between the filgrastim products studied.


Subject(s)
Biosimilar Pharmaceuticals/chemistry , Filgrastim/chemistry , Hematologic Agents/chemistry , Biosimilar Pharmaceuticals/pharmacology , Cell Line , Cell Proliferation/drug effects , Drug Contamination , Drug Stability , Filgrastim/pharmacology , Hematologic Agents/pharmacology , Humans , Protein Stability
2.
Nat Commun ; 7: 13397, 2016 11 08.
Article in English | MEDLINE | ID: mdl-27824045

ABSTRACT

Many biopharmaceutical products exhibit extensive structural micro-heterogeneity due to an array of co-occurring post-translational modifications. These modifications often effect the functionality of the product and therefore need to be characterized in detail. Here, we present an integrative approach, combining two advanced mass spectrometry-based methods, high-resolution native mass spectrometry and middle-down proteomics, to analyse this micro-heterogeneity. Taking human erythropoietin and the human plasma properdin as model systems, we demonstrate that this strategy bridges the gap between peptide- and protein-based mass spectrometry platforms, providing the most complete profiling of glycoproteins. Integration of the two methods enabled the discovery of three undescribed C-glycosylation sites on properdin, and revealed in addition unexpected heterogeneity in occupancies of C-mannosylation. Furthermore, using various sources of erythropoietin we define and demonstrate the usage of a biosimilarity score to quantitatively assess structural similarity, which would also be beneficial for profiling other therapeutic proteins and even plasma protein biomarkers.


Subject(s)
Biosimilar Pharmaceuticals/analysis , Glycoproteins/analysis , Mass Spectrometry/methods , Proteomics/methods , Amino Acid Sequence , Erythropoietin/chemistry , Erythropoietin/metabolism , Glycoproteins/chemistry , Humans , Properdin/chemistry , Properdin/metabolism , Protein Processing, Post-Translational , Recombinant Proteins/chemistry , Recombinant Proteins/metabolism
3.
J Pharm Sci ; 105(2): 542-550, 2016 Feb.
Article in English | MEDLINE | ID: mdl-26869417

ABSTRACT

Comprehensive physicochemical characterization and biological assays are essential parts in assessing quality attributes of biologicals. Here, we compared the quality of different marketed recombinant human erythropoietin (epoetin) products: originators, Eprex and NeoRecormon as well as 2 biosimilars, Retacrit and Binocrit. In addition, assessment of batch-to-batch variability was included by collecting 2 or more batches of each product. Common assays which included sodium dodecyl sulfate-polyacrylamide gel electrophoresis, high-performance size-exclusion chromatography, asymmetrical flow field-flow fractionation, capillary zone electrophoresis, and potency testing were used. Of the tested products and among batches of single products, variations in epoetin content, isoform profiles, and potency were found. Ultimately, this study demonstrated the high quality of epoetin products with some degree of variation among products and batches, confirming the "similar but not identical" paradigm of biologicals.


Subject(s)
Biosimilar Pharmaceuticals/standards , Chemistry, Pharmaceutical/methods , Epoetin Alfa/standards , Erythropoietin/standards , Animals , Biosimilar Pharmaceuticals/analysis , Biosimilar Pharmaceuticals/chemistry , Epoetin Alfa/analysis , Epoetin Alfa/chemistry , Erythropoietin/analysis , Erythropoietin/chemistry , Female , Humans , Mice , Mice, Inbred BALB C , Recombinant Proteins/analysis , Recombinant Proteins/chemistry , Recombinant Proteins/standards , Therapeutic Equivalency
4.
J Pharm Sci ; 103(5): 1367-74, 2014 May.
Article in English | MEDLINE | ID: mdl-24619587

ABSTRACT

Mouse models are commonly used to assess the immunogenicity of therapeutic proteins and to investigate the immunological processes leading to antidrug antibodies. The aim of this work was to develop a transgenic (TG) Balb/c mouse model for evaluating the immunogenicity of recombinant human insulin (insulin) formulations. Validation of the model was performed by measuring the antibody response against plain and particulate insulin in TG and nontransgenic (NTG) mice. Intraperitoneal administration of insulin (20 µg/dose, 12 doses over a period of 4 weeks) did not break the immune tolerance of the TG mice, whereas it did elicit antibodies in NTG mice. The immune tolerance of TG mice could be circumvented, albeit at low titers, by administering insulin covalently bound to 50-nm polystyrene nanoparticles. The TG mouse model was employed to compare the immunogenicity of oxidized aggregated insulin, oxidized nonaggregated insulin, and three commercially available formulations of insulin variants (i.e., Levemir®, Insulatard®, and Actrapid®). Oxidized insulin, aggregated or nonaggregated, was moderately immunogenic in TG mice (50% and 33% responders, respectively), whereas the immunogenicity of the commercial formulations was low. This model can be used to compare the immunogenicity of insulin formulations and to study immune mechanisms of antibody formation against insulin.


Subject(s)
Antibody Formation/immunology , Insulin/immunology , Mice, Transgenic/immunology , Recombinant Proteins/immunology , Animals , Chemistry, Pharmaceutical/methods , Humans , Immune Tolerance/immunology , Insulin/chemistry , Mice , Mice, Inbred BALB C , Nanoparticles/chemistry , Particle Size , Polystyrenes/chemistry , Recombinant Proteins/chemistry
5.
Pharm Res ; 31(5): 1210-8, 2014 May.
Article in English | MEDLINE | ID: mdl-24258097

ABSTRACT

PURPOSE: The high prevalence of pure red cell aplasia in Thailand has been associated with the sharp increase in number of recombinant human erythropoietin (rhEPO) copy products, based on a classical generic regulatory pathway, which have entered the market. This study aims to assess the quality of rhEPO copy products being used in Thailand. METHODS: Twelve rhEPO copy products were purchased from pharmacies in Thailand, shipped under controlled cold chain conditions to the Netherlands and characterized using (1) high performance size-exclusion chromatography, (2) asymmetrical flow field-flow fractionation, (3) sodium dodecyl sulfate polyacrylamide gel electrophoresis in combination with (4) Western blotting and additionally tested for (5) host cell protein impurities as well as (6) endotoxin contamination. RESULTS: Some of the tested rhEPO copy products showed high aggregate levels and contained a substantial amount of protein fragments. Also, one of rhEPO copy products had a high endotoxin level, exceeding the FDA limit. CONCLUSIONS: Our observations show that some of the tested copy products on the Thai market differ significantly from the originator rhEPO product, Epogen®. This comparison study supports a link between the quality attributes of copy rhEPO products and their immunogenicity.


Subject(s)
Erythropoietin/pharmacology , Blotting, Western , Chromatography, Gel , Chromatography, High Pressure Liquid , Electrophoresis, Polyacrylamide Gel , Erythropoietin/isolation & purification , Fractionation, Field Flow , Humans , Recombinant Proteins/isolation & purification , Recombinant Proteins/pharmacology , Thailand
SELECTION OF CITATIONS
SEARCH DETAIL
...